OCT 15, 2025 1:00 PM PDT

Optimizing iPSC-derived cell therapy development for allogeneic and therapeutic applications

Sponsored by: Thermo Fisher Scientific
Speaker

Abstract

With iPSCs continuing to emerge as an important source of starting materials for cell therapy developers, it is crucial to tackle key remaining challenges relating to cell culture scalability and differentiation, and to optimize iPSC-derived cell therapy production workflows.

Dr. Farah will discuss strategies to address a range of issues and bottlenecks in iPSC-derived cell therapy development. Using iPSC-derived CAR-NK (iNK) cells as an example, he will explore solutions for successful iPSC culturing and scale-up before sharing an optimized multi-step protocol to differentiate iPSCs to HSPCs to NK cells.


You May Also Like
Loading Comments...
Event Countdown
  • 0 Days
  • 0 Hours
  • 0 Minutes
  • 0 Seconds